PHAT - Phathom Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

PHAT is currently covered by 4 analysts with an average price target of $15.99. This is a potential upside of $13.59 (566.25%) from yesterday's end of day stock price of $2.4.

Phathom Pharmaceuticals's activity chart (see below) currently has 32 price targets and 70 ratings on display. The stock rating distribution of PHAT is 96% BUY and 4% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 20.37% with an average time for these price targets to be met of 35.22 days.

Highest price target for PHAT is $28, Lowest price target is $12, average price target is $18.

Most recent stock forecast was given by YATIN SUNEJA from GUGGENHEIM on 02-May-2025.

Currently out of the existing stock ratings of PHAT, 48 are a BUY (96%), 2 are a HOLD (4%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$12

$9.24 (334.78%)

6 days ago
(02-May-2025)

1/7 (14.29%)

$9.24 (334.78%)

152

Buy

$20

$17.24 (624.64%)

$28

6 days ago
(02-May-2025)

0/7 (0%)

$17.24 (624.64%)

Buy

$28

$25.24 (914.49%)

$28

17 days ago
(21-Apr-2025)

0/43 (0%)

$24.1 (617.95%)

Hold

$12

$9.24 (334.78%)

$10

8 months 29 days ago
(09-Aug-2024)

6/7 (85.71%)

$0.25 (2.13%)

29

Buy

$30

$27.24 (986.96%)

$35

2 years 2 months 7 days ago
(01-Mar-2023)

0/4 (0%)

$20.99 (232.96%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is PHAT (Phathom Pharmaceuticals) average time for price targets to be met?

On average it took 35.22 days on average for the stock forecasts to be realized with a an average price target met ratio 20.37

Which analyst has the current highest performing score on PHAT (Phathom Pharmaceuticals) with a proven track record?

PAUL CHOI

Which analyst has the current lower performing score on PHAT (Phathom Pharmaceuticals) with a proven track record?

MATTHEW CAUFIELD

Which analyst has the most public recommendations on PHAT (Phathom Pharmaceuticals)?

Paul Choi works at GOLDMAN SACHS and has 6 price targets and 5 ratings on PHAT

Which analyst is the currently most bullish on PHAT (Phathom Pharmaceuticals)?

Prakhar Agrawal with highest potential upside - $52.74

Which analyst is the currently most reserved on PHAT (Phathom Pharmaceuticals)?

Umer Raffat with lowest potential downside - -$0

Phathom Pharmaceuticals in the News

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company’s Board of Directors has approved the grant...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?